Context.—

The global impact of the new 2018 American Society of Clinical Oncology/College of American Pathologists human epidermal growth factor receptor 2 (HER2) practice guideline update on the overall HER2 status designation, compared with the prior 2013 iteration, is unknown.

Objectives.—

To report the quantitative impact of the new guideline on HER2 status distribution.

Design.—

The analysis comprised a retrospective cohort of patients from the author's institution, combined with other peer-reviewed publications that assessed the impact of the 2018 guideline in relation to the 2013 guideline.

Results.—

Our study revealed that the new guideline led to an average 9% reclassification rate for the overall HER2 status, with a net gain in overall HER2 negative designation. This is largely due to reclassification of the equivocal (Group 4) groups. Unexpectedly, infrequent but consistent discordance between Group 1/5 and fluorescence in situ hybridization results are observed across studies (1.8%; 73 of 3965 cases where fluorescence in situ hybridization and immunohistochemistry are both reported).

Conclusions.—

Early clinical recognition of these resultant changes, including emerging issues of tumor heterogeneity, and potential discordance between immunohistochemistry to fluorescence in situ hybridization, is important for accurate clinical assessment of individual HER2 test results.

This content is only available as a PDF.

Author notes

The authors have no relevant financial interest in the products or companies described in this article.